A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2/3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
393actual
Sites
112
Countries
Australia, China, Denmark +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-11-26 | actual | When the study began enrolling |
| Primary completion | 2024-01-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2018-10-16 | actual | When this record first appeared on the registry |
| Results posted | 2025-03-06 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prostate Cancer
Interventions
- Drug: Abemaciclib — also filed as LY2835219
- Drug: Placebo
- Drug: Abiraterone acetate
- Drug: Prednisone
Primary outcome
what the primary-completion date above is the date OFRadiographic Progression Free Survival (rPFS)
measured From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (Up to 60 Months)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-04-30 · 7.4 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-10-25 · 600 KB · SAP_001.pdf
Publications
- PMID 41167216 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed